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Introduction
Breast cancer is one of the most prevalent types of cancer
in women especially in the United States and other
Western countries. The risk of developing breast cancer is
reduced by 50% in women who have undergone a full-
term pregnancy by the age of 20, as compared with nulli-
parous women [1–3]. This phenomenon of parity
protection against breast cancer is observed universally
among women from all ethnic groups. The protective
effect of parity is not only observed in humans, but is also
found in rats and mice [4–9].
The mechanism involved in parity protection against
breast cancer is still not defined. Understanding the mech-
anism would help in developing strategies for the preven-
tion of breast cancer. Several studies have supported the
hypothesis that the mammary glands in parous rats have
decreased proliferation, have higher capacity to repair
DNA, have lower binding of carcinogen, and are more dif-
ferentiated as compared with the mammary gland of age-
matched virgin rats [10–13]. On the contrary, other
studies have found no difference in the structure, in the
proliferative activity, or in carcinogen binding to DNA of
hCG = human chorionic gonadotropin; IL = interleukin; MNU = N-methyl-N-nitrosourea.
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Abstract
Introduction Women who have undergone a full-term
pregnancy before the age of 20 have one-half the risk of
developing breast cancer compared with women who have
never gone through a full-term pregnancy. This protective effect
is observed universally among women of all ethnic groups.
Parity in rats and mice also protects them against chemically
induced mammary carcinogenesis.
Methods Seven-week-old virgin Lewis rats were given
N-methyl-N-nitrosourea. Two weeks later the rats were treated
with natural or synthetic estrogens and progestins for
7–21 days by subcutaneous implantation of silastic capsules.
Results In our current experiment, we demonstrate that short-
term sustained exposure to natural or synthetic estrogens
along with progestins is effective in preventing mammary
carcinogenesis in rats. Treatment with 30 mg estriol plus 30 mg
progesterone for 3 weeks significantly reduced the incidence
of mammary cancer. Short-term exposure to ethynyl estradiol
plus megesterol acetate or norethindrone was effective in
decreasing the incidence of mammary cancers. Tamoxifen plus
progesterone treatment for 3 weeks was able to confer only a
transient protection from mammary carcinogenesis, while
2-methoxy estradiol plus progesterone was effective in
conferring protection against mammary cancers.
Conclusions The data obtained in the present study
demonstrate that, in nulliparous rats, long-term protection against
mammary carcinogenesis can be achieved by short-term
treatments with natural or synthetic estrogen and progesterone
combinations.
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mammary cells between parous rats and age-matched
virgin rats [5,6].
During pregnancy, several hormones in a cohort cause
proliferation and differentiation of the mammary gland.
There is a dramatic increase in the levels of circulating
estrogens, progesterone, prolactin, growth hormone and
placental lactogens. As a consequence of these hormonal
exposures, the mammary gland proliferates and differenti-
ates in preparation for lactation [14]. At the end of preg-
nancy, the mammary gland under the influence of
lactogenic hormones becomes fully lactational. After
weaning of the offspring, the highly differentiated lobu-
loalveolar structures subsequently involute as a result of
the decrease in lactogenic hormones [14].
Pregnancy before or soon after exposure to a chemical
carcinogen is protective against mammary cancers in
rodents. Russo and colleagues [10–13] have suggested
that the protective effect is due to the differentiation of
target structures during pregnancy. Others have reported
that there are persistent alterations in the levels of circulat-
ing hormones in parous women and rats compared with
their respective age-matched controls. The blood level of
prolactin is reduced in parous women [15,16]. Thordarson
and colleagues [17] have reported a decrease in the cir-
culating concentration of growth hormone in parous rats.
They have also demonstrated that mammary glands of
parous rats have decreased levels of estrogen receptors
and epidermal growth factor receptors compared with
age-matched virgin rats. These persistent alterations might
be involved in refractoriness to mammary carcinogenesis
in parous rats.
Administration of high doses of estradiol and proges-
terone in combination [18–23] or of human chorionic
gonadotropin [24] before or after carcinogen treatment
was protective against mammary carcinogenesis in rats.
The widely accepted explanation for hormone-induced
refractoriness to mammary carcinogenesis is that either
the target cells for cancer in the mammary gland are
altered to a nonsusceptible state by early hormone treat-
ment [23], or that the initiated cells are differentiated fol-
lowing carcinogen treatment [20,22] or are killed following
hormone treatment [24]. We have recently demonstrated
that short-term treatment with high pregnancy levels of
estradiol with or without progesterone is highly effective in
decreasing the mammary cancer incidence [25,26]. There
are also reports implicating alteration in gene expressions
as an explanation for the protective effect of pregnancy or
the protective hormone treatments against mammary
cancer [27–30].
The objective of the present study was to examine
whether different kinds of natural and/or synthetic estro-
gens and progestins at different doses and durations
would modify the incidence of mammary carcinogenesis
following exposure to N-methyl-N-nitrosourea (MNU). We
tested estriol alone or in combination with progesterone
because it is known that estriol levels increase during
pregnancy [31]. We also used the synthetic compounds
(ethynyl estradiol in combination with megesterol acetate
or norethindrone). These compounds are used in combi-
nation oral contraceptives, and the risk of uterine and
ovarian cancers are reduced by almost 50% in women
using contraceptives containing these compounds
[32,33]. Moreover, oral contraceptives do not confer an
increased breast cancer risk [34].
We also wanted to test the protective effect, if any, of
short-term treatment with tamoxifen combined with prog-
esterone. Long-term treatment with tamoxifen is used as a
hormonal therapy for breast cancers [35]. The estrogen
metabolites, 2-hydroxy estradiol and 2-methoxy estradiol,
which have been reported to inhibit angiogenesis and
tumor cell growth [36], were administered alone or in
combination with progesterone. Since it is known that
estradiol metabolites bind with low affinity to estradiol
receptors [37–39] and they are less potent estrogens
[40,41] than the parent compound, we attempted to
determine whether a weak estrogen alone or in combina-
tion with progesterone would be able to mimic the protec-
tive effect of pregnancy protection against mammary
cancers. We hypothesized that short-term treatment with
different estrogens alone or in combination with prog-
estins would be able to mimic the protective effect of
pregnancy and to reduce the incidence of mammary car-
cinogenesis in these treated rats in comparison with
untreated controls following exposure to MNU.
Materials and methods
Animals
Virgin Lewis rats were purchased from Harlan Sprague
Dawley (Indianapolis, IN, USA and San Diego, CA, USA).
The rats were housed in a temperature-controlled room with
a 12-hour light and 12-hour dark schedule. They were given
food (Teklad, Madison, WI, USA) and water ad libitum.
Carcinogen treatment
A single intraperitoneal injection of MNU (Ashe Stevens,
Detroit, MI, USA) at a dose of 50 mg/kg body weight was
given to all rats at 7 weeks of age. MNU was dissolved in
physiological saline that had been adjusted to pH 5.0 [42].
Hormone treatment
All the hormone treatments in the following experiments
were given 2 weeks after the administration of the carcino-
gen. The hormones, natural or synthetic, were packed in
individual silastic capsules (0.078 inch ID×0.125 inch OD,
2 cm long; Dow Corning, Midland, MI, USA). Rats that
received a combination hormone treatment were
implanted with individual capsules containing the respec-
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tive hormone. The hormones were packed in the silastic
capsules in a cellulose matrix, except for the 30 mg dose
that was packed with the hormone alone. The control
group received empty silastic capsules. All silastic cap-
sules were implanted subcutaneously dorsally. There were
10–13 rats in the different hormone treatment groups.
Effects of natural and synthetic estrogens and
progestins on the prevention of mammary
carcinogenesis after exposure to MNU
Effect of estriol plus or minus progesterone on MNU-induced
mammary carcinogenesis
When the rats were 9 weeks old they were divided into
five groups, receiving the following treatments: (1) control,
(2) 30 mg estriol, (3) 200 µg estriol (Sigma, St Louis, MO,
USA), (4) 30 mg estriol plus 30 mg progesterone (Sigma),
and (5) 200 µg estriol plus 30 mg progesterone in silastic
capsules. Each treatment was continued for 1 or 3 weeks.
Effect of ethynyl estradiol plus megesterol acetate or
norethindrone on mammary carcinogenesis
Rats were implanted with silastic capsules containing
100 µg ethynyl estradiol (Sigma) and 30 mg megesterol
acetate (Sigma) or norethindrone (Sigma). Treatment with
100 µg ethynyl estradiol plus 30 mg megesterol acetate
was given for both 1 and 3 weeks. Treatment with 100 µg
ethynyl estradiol plus norethindrone was given for 1 week.
Effect of tamoxifen plus progesterone on MNU-induced
carcinogenesis
Rats were implanted with silastic capsules containing
30mg tamoxifen (Sigma) and 30mg progesterone. The
silastic capsules were removed after 3 weeks of treatment.
Effect of 2-hydroxy estradiol or 2-methoxy estradiol with or
without progesterone on mammary carcinogenesis induced by
MNU
The rats were divided into five groups and were treated as
follows: (1) control, (2) 2 mg 2-hydroxy estradiol (Ster-
aloids, Newport, RI, USA), (3) 2 mg 2-hydroxy estradiol
plus 30 mg progesterone, (4) 2 mg 2-methoxy estradiol
(Steraloids), and (5) 2 mg 2-methoxy estradiol plus 30 mg
progesterone.
Mammary carcinogenesis
Rats were palpated once every week after carcinogen
exposure for 9 months to monitor for mammary cancer
development. Histopathological examination was per-
formed to confirm the carcinomatous nature of the palpa-
ble tumors.
Statistics
The effects of the different hormonal treatments were ana-
lyzed using the chi-square test for 2 × 2 contingency
tables and the Student t test. P < 0.05 was considered
significant.
Results
Effect of estriol alone or with progesterone on
mammary cancer incidence and multiplicity
In the present study to determine whether estriol alone or
in combination with progesterone could be protective
against MNU-induced carcinogenesis, rats treated with
30 mg estriol plus 30 mg progesterone for 3 weeks had a
significantly reduced incidence of mammary cancers
(25%). The treated rats had an average of 0.4 cancers per
rat 9 months after MNU injection, compared with control
rats that had a high mammary cancer incidence of 80%
and a cancer multiplicity of 1.7 cancers per rat. Treat-
ments with estriol alone for 1 week at a dose of 30 mg
(83%) or 200 µg (100%), or with 200 µg estriol plus
30 mg progesterone (75%) did not prevent MNU-induced
mammary carcinogenesis. Even when the same doses
were given for 3 weeks, the mammary cancer incidence
was 64%, 75% and 82%, respectively. Mammary cancer
multiplicity in these treatments was not significantly differ-
ent from that of the controls (Table 1).
Effect of ethynyl estradiol plus megesterol acetate or
norethindrone on mammary cancer incidence and
multiplicity
The mammary cancer incidence (23%) and the average
number of cancers per rat (0.2 cancers) were significantly
lower in rats treated with ethynyl estradiol and megesterol
acetate for 3 weeks compared with controls that had a
mammary cancer incidence of 75% and had 1.5 cancers
per rat. The same combination of hormones given for
1 week was effective in preventing mammary carcinogen-
esis for the first 6 months, when the mammary cancer inci-
dence was only 8%, but by 9 months the incidence had
increased to 38%. However, the average number of
cancers per rat in the 1-week treatment group (0.4 cancers)
was significantly lower than the controls. Treatment with
ethynyl estradiol and norethindrone for 1 week was effective
in drastically decreasing the mammary cancer incidence
(25%) and the average number of cancers per rat
(0.2 cancers) compared with the controls (Table 2).
Effect of tamoxifen plus progesterone on mammary
cancer incidence and multiplicity
Treatment with tamoxifen and progesterone for 3 weeks
was effective in preventing mammary carcinogenesis for
the first 6 months after MNU injection, when the incidence
reached 30%. Nine months after MNU injection the
mammary cancer incidence was 58% and the multiplicity
was 0.9, which was not significantly lower than the con-
trols in cancer incidence or multiplicity (Table 2).
Effect of 2-hydroxy estradiol and 2-methoxy estradiol
with or without progesterone on mammary cancer
incidence and multiplicity
Administrations of estrogen metabolites alone or in combi-
nation with progesterone were ineffective in preventing
Available online http://breast-cancer-research.com/content/6/1/R31
MNU-induced mammary carcinogenesis, except for the
combination of 2-methoxy estradiol plus progesterone.
Two milligrams of 2-hydroxy estradiol (80%) alone or in
combination with 30 mg progesterone (60%) did not
lower the mammary cancer incidence compared with the
controls (75%). Treatment with 2 mg 2-methoxy estradiol
alone for 3 weeks did not decrease the mammary cancer
incidence (60%) compared with the controls. However,
when 2 mg 2-methoxy estradiol was given along with
30 mg progesterone the mammary cancer incidence was
lowered (30%) in comparison with the controls (Table 3).
This treatment also lowered the average number of
cancers per rat (0.4 cancers) compared with the controls
(1.3). Even though 2-methoxy estradiol alone was not
effective in decreasing the cancer incidence, it was effec-
tive in decreasing the average number of cancers per rat
by almost 50% (0.7 cancers). Treatments with 2-hydroxy
estradiol alone or in combination with progesterone did
not affect cancer multiplicity compared with the controls
(Table 3).
Discussion
The results of the present study show that short-term
treatments with natural or synthetic ovarian steroids are
effective in long-term protection against MNU-induced
mammary carcinogenesis in female Lewis rats. It is well
established that full-term pregnancy is very effective in
preventing mammary carcinogenesis in humans, rats and
mice [1–9]. We have previously demonstrated that 1 and
3 weeks of treatment with estradiol 17β with or without
progesterone is highly effective in reducing the mammary
cancer incidence and cancer multiplicity [25,26].
Lemon [43] demonstrated that administration of estriol
inhibited 7,12-dimethylbenzanthracene-induced mammary
carcinogenesis in rats. The data from our studies show
that a high dose of estriol plus progesterone administered
for 3 weeks provides long-term protection against
mammary carcinogenesis. A similar combination given for
1 week was not effective in reducing mammary carcino-
genesis. Estriol alone or at a lower dose in combination
Breast Cancer Research    Vol 6 No 1 Rajkumar et al.
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Table 1
Effect of estriol on mammary carcinogenesis
Mammary cancer Rats with mammary Average number of
Treatment Duration incidence cancer (%) cancers per rat
Control 3 weeks 8/10 80 1.7 ± 0.4
30 mg estriol 1 week 10/12 83 1.6 ± 0.3
200 µg estriol 1 week 11/11 100 1.7 ± 0.3
30 mg estriol + 30 mg progesterone 1 week 7/12 58 1.2 ± 0.3
200 µg estriol + 30 mg progesterone 1 week 9/12 75 1.6 ± 0.3
30 mg estriol 3 weeks 7/11 64 1.0 ± 0.3
200 µg estriol 3 weeks 9/12 75 1.6 ± 0.3
30 mg estriol + 30 mg progesterone 3 weeks 3/12* 25 0.4 ± 0.2*
200 µg estriol + 30 mg progesterone 3 weeks 9/11 82 2.0 ± 0.4
Rats were treated with N-methyl-N-nitrosourea at 7 weeks of age. At 9 weeks of age, the rats were treated with hormones for 1 or 3 weeks. Control
rats received empty silastic capsules. *P < 0.05 compared with controls.
Table 2
Effect of synthetic estrogens and progestins on mammary carcinogenesis
Mammary cancer Rats with mammary Average number of
Treatment Duration incidence cancer (%) cancers per rat
Control 3 weeks 9/12 75 1.5 ± 0.3
100 µg eE + 30 mg megesterol 3 weeks 3/13* 23 0.3 ± 0.2*
30 mg tamoxifen + 30 mg progesterone 3 weeks 7/12 58 0.9 ± 0.3
100 µg eE + 30 mg megesterol 1 week 5/13 38 0.4 ± 0.1*
100 µg eE + 30 mg norethindrone 1 week 3/12* 25 0.2 ± 0.1*
Rats were treated with N-methyl-N-nitrosourea at 7 weeks of age. At 9 weeks of age, the rats were treated with hormones for 1 or 3 weeks. Control
rats received empty silastic capsules. eE, 17α-ethynyl estradiol. *P < 0.05 compared with controls.
with progesterone did not have a protective effect. The
data suggest that high levels of estriol in combination with
progesterone administered for 3 weeks is effective while a
lower dose and a lower duration of treatment were ineffec-
tive in preventing mammary carcinogenesis, indicating that
prevention of mammary cancer depends on the dose and
duration of hormones used.
We demonstrated earlier that the pregnancy level of estra-
diol with or without progesterone is efficient in conferring
protection against mammary cancers. Huggins and col-
leagues [18] and Grubbs and colleagues [20] previously
reported that high levels of estradiol and progesterone
given daily for 40 days, beginning 2 weeks after the
administration of carcinogen, inhibited the appearance of
mammary cancers in rats treated with 7,12-dimethylben-
zanthracene or MNU. Huggins and colleagues suggested
that the potential cancer cells were killed due to differen-
tial sensitivity to high levels of ovarian steroids, while
Grubbs and colleagues suggested that the protection
offered by ovarian steroids was due to differentiation of
preneoplastic cells.
Russo and Russo [11,13] have shown that human chori-
onic gonadotropin (hCG) treatment also provided protec-
tion against mammary carcinogenesis. It has also been
suggested that protective hormone treatments result in
persistent changes in the intracellular pathways, which
mediate proliferation responses to carcinogens [23]. Thor-
darson and colleagues [17] demonstrated that parous rats
given carcinogen and followed by continuous treatment
with estradiol and progesterone had a high cancer inci-
dence. These data suggest that parous mammary epithe-
lial cells do undergo transformation, but they have a
reduced promotional environment. Short-term hCG treat-
ment resulted in activation of several apoptotic genes like
TRMP2, IL-1β converting enzyme, p53, c-myc and bcl-XS
[27]. You and colleagues [44] suggested that hCG-con-
ferred protection against mammary cancer was due to an
increase in connexin 26, a tumor suppressor gene.
D’Cruz and colleagues have reported persistent downregu-
lation of many growth-promoting factors (amphiregulin,
pleiotrophin and insulin-like growth factor 1) and upregula-
tion of genes involved in differentiation (whey acidic protein,
caesins, lactoferrin) and in immune response (immunoglob-
ulins, macrophage metalloelastase, macrophage expressed
gene 1), and upregulation of transforming growth factor β3
and several of its transcriptional targets (clusterin, Eta, Id2)
[28]. Short-term estradiol plus progesterone treatment per-
sistently upregulated RbAp46 and G.B7, genes implicated
in chromatin remodeling [29]. Medina and colleagues [30]
attributed an increment in p53 gene expression as one of
the mechanisms for hormone-induced protection.
Our studies with synthetic estrogenic and progestogenic
compounds show that short-duration treatments are suffi-
cient to prevent mammary carcinogenesis. Ethynyl estra-
diol and norethindrone administered for 1 week are highly
effective in preventing the occurrence of mammary
cancers. The latent period for the appearance of mammary
cancers was very long as no mammary cancer appeared
for the first 7 months after the administration of the car-
cinogen. A combination of 100 µg ethynyl estradiol and
30 mg megesterol acetate was able to prevent MNU-
induced mammary carcinogenesis when given for
3 weeks. The same combination was less effective when
administered for only 1 week. This indicates that the pre-
ventive effect of these compounds depends on the dose,
the duration and the nature of treatments. Medroxyproges-
terone acetate did not increase the risk of carcinoma
development when administered to virgin rats at the clini-
cal dose used for contraception. However, a 10-fold dose
increase resulted in a higher tumorigenic response, while
a similar dose of the mostly estrogenic northynodrel-
mestranol was protective [45,46].
These synthetic hormones are used in oral contraceptives
and have been found to decrease the incidence of uterine
and ovarian cancers [33]. Previous studies have reported




Effect of estrogen metabolites on mammary carcinogenesis
Mammary cancer Rats with mammary Average number of
Treatment Duration incidence cancer (%) cancers per rat
Control 3 weeks 9/12 75 1.3 ± 0.5
2 mg 2-hydroxy estradiol 3 weeks 8/10 80 1.4 ± 0.3
2 mg 2-hydroxy estradiol + 30 mg progesterone 3 weeks 6/10 60 1.5 ± 0.5
2 mg 2-methoxy estradiol 3 weeks 6/10 60 0.7 ± 0.2
2 mg 2-methoxy estradiol + 30 mg progesterone 3 weeks 3/10* 30 0.4 ± 0.2
Rats were treated with N-methyl-N-nitrosourea at 7 weeks of age. At 9 weeks of age, the rats were treated with hormones for 3 weeks. Control rats
received empty silastic capsules. *P < 0.05 compared with controls.
women taking oral contraceptives [47,48]. It has recently
been reported that oral contraceptives do not increase the
risk of breast cancers [34]. In our study, we found that
these synthetic hormones given for a short duration are
capable of preventing mammary carcinogenesis. When
we used tamoxifen plus progesterone treatment, there
was a significant difference in mammary cancer incidence
for the first 6 months. By the end of 9 months, however,
there were no differences between the treated group and
the control group of rats. This combination had some pre-
ventive effect on mammary cancers but it was a short-term
effect. In previous studies, tamoxifen treatment given con-
tinuously prevents mammary carcinogenesis [35] and the
short-term treatment, which we administered here, was
not sufficient to prevent mammary cancers. Jordan and
colleagues [49] also reported that short-term treatment
with various doses of tamoxifen was not able to confer
protection against chemical carcinogen-induced mammary
carcinogenesis. Jordan [50] later suggested that tamox-
ifen appears to act as an inhibitor of the tumor cell cycle
rather than as a tumoricidal agent in the rat model.
It has been reported that certain estrogen metabolites have
a preventive effect in the process of mammary carcinogene-
sis [36]. It has been reported that 2-hydroxy estradiol is a
potent inhibitor of tumor cell proliferation [51–53] and
angiogenesis [52,53]. In addition, 2-methoxy estradiol also
inhibits the growth of many cancer cell lines [51–53]. In the
current study, we investigated the effects of two estrogen
metabolites on mammary carcinogenesis (namely, 2-hydroxy
estradiol and 2-methoxy estradiol) at a dose of 2 mg alone
or in combination with 30mg progesterone. Neither
metabolite alone nor 2-hydroxy estradiol in combination with
progesterone was effective in preventing mammary cancers.
A combination of 2-methoxy estradiol and progesterone,
however, was able to decrease the mammary cancer inci-
dence. Both these estrogen metabolites bind to the estro-
gen receptor, but with a markedly reduced binding affinity
as compared with estradiol [37–39]. Also, both these
metabolites possess much weaker estrogenic potency than
estradiol [40,41]. The reason for the lack of protective effect
may be that the reduced binding affinity and weaker
potency or the dose of the metabolites we used was not
sufficient to produce a strong estrogenic effect.
Lamartiniere and colleagues [54] have shown that phytoe-
strogen genistein protects against mammary cancer. They
also showed that the effect was dose dependent. Since
genistein is a weak estrogen, higher doses were needed to
achieve protection. It is clear from our data and from data of
previous studies that a mid- to late-pregnancy level of estro-
gen alone or in combination with progesterone is necessary
for the protective effect against chemically induced
mammary cancers. The protective effect of estrogen plus
progestin combinations, whether natural or synthetic, could
be similar to parity-induced protection against mammary
cancers. It has been shown that there is permanent
decrease in the mammogenic hormones, growth hormone
and prolactin in parous rats [18,55]. Parous women also
have reduced blood levels of prolactin compared with age-
matched nulliparous women [15,16]. The reduced levels of
mammogenic hormones like prolactin and growth hormone
resulting in a decrease in promotional environment and the
altered sensitivity of the mammary glands to estradiol may
also be factors involved in the protective effect against
mammary carcinogenesis. Unlike many of the earlier studies
where protection was achieved against mammary cancer by
administration of high doses of estradiol plus progesterone
for a longer duration, we have been able to demonstrate
that administration of estrogens and progestins (natural or
synthetic) for a short duration is as effective as high-dose
combinations and long-duration treatments in preventing
mammary cancers.
Conclusions
The overall data from the present study suggest that a
variety of estrogenic compounds are able to protect
against chemical-induced mammary carcinogenesis. Short-
term treatment with low doses of strong estrogenic com-
pounds in combination with progestins are highly effective
in preventing mammary carcinogenesis. Our treatments for
1 week with synthetic estrogens and progestins indicate
that treatments shorter than the length of gestation in rats
will also be able to induce a long-term protection against
mammary carcinogenesis. This would help in developing
new strategies for prevention of mammary cancers using
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